A ten-year study led by Imperial College London has established that focal therapy for prostate cancer provides cancer control comparable to traditional surgery or radiotherapy while reducing the risk of life-altering side effects by five-fold. Despite these clinical findings, data from The Focal Therapy Clinic indicates that 93% of patients remain unaware of this option before diagnosis, often learning of it through independent research rather than clinical consultations.
Clinical Efficacy and Long-Term Cancer Control
The research, which tracked nearly 3,500 patients over a decade, represents the largest and longest dataset on focal therapy to date. According to Raj Nigam, a consultant urologist at The Focal Therapy Clinic and senior co-author of the study, the data confirms the treatment is a viable, safe alternative for a broader range of patients than previously assumed.
The study specifically highlights that high-risk patients—who comprised roughly 25% of the cohort—can be treated safely. For these individuals, the therapy significantly lowers the incidence of incontinence, erectile dysfunction, and rectal complications compared to radical prostatectomy or radiotherapy. These findings challenge the previous assumption that focal therapy was only suitable for about 20% of the patient population.
Did you know?
Before undergoing treatment, 84% of prostate cancer patients reported significant anxiety regarding potential erectile dysfunction, with 29% noting they thought about the possibility constantly.
Addressing the Information Gap in Prostate Cancer Care
Despite the therapeutic benefits, patients frequently report a lack of awareness regarding their treatment choices. Survey data from The Focal Therapy Clinic reveals that 32% of men had no knowledge of any treatment options before their diagnosis, and 45% were unaware that prostate cancer can present without symptoms.
The current clinical landscape often defaults to established radical procedures. Only 5% of surveyed patients reported being offered focal therapy at the point of diagnosis. In contrast, 31% were offered surgery, and another 31% were directed toward hormone or radiotherapy. Consequently, 64% of those who eventually received focal therapy discovered the treatment through their own online research.
The Path Toward Guideline Integration
Because focal therapy is not currently listed as a primary treatment option, the NHS is under no formal obligation to provide it. This has resulted in limited access, restricted to just 10 centres across England.
Nigam notes that the historic resistance to including focal therapy in NICE guidelines was due to a perceived lack of long-term evidence. With the publication of the ten-year study, campaigners are now urging a review of these guidelines to ensure equitable access. While the study does not guarantee immediate changes to NHS protocol, it provides the robust clinical data necessary to shift the conversation among clinicians and policymakers.
Frequently Asked Questions
- What is focal therapy? It is a treatment approach that targets only the cancerous areas of the prostate, rather than the entire gland, to preserve surrounding tissue and function.
- Why is it not offered everywhere? Currently, focal therapy is not included in NICE guidelines for primary prostate cancer treatment, which limits the number of NHS sites offering the procedure.
- Is focal therapy effective for high-risk patients? Yes. According to the Imperial College London study, carefully selected high-risk patients can be treated safely with outcomes comparable to more radical interventions.
If you or a loved one are facing a prostate cancer diagnosis, ask your consultant specifically about “focal therapy” and whether you meet the clinical criteria for this treatment to ensure you are fully informed of all available options.
Have you or a family member navigated the complexities of prostate cancer treatment? Share your experience in the comments below or subscribe to our health newsletter for the latest updates on oncology research.
Related reading